Early Notification and Brand Change Update Sodium Chloride Inj 0.9%
As advised via PHARMAC Tender Results of 30 April 2019 there is to be a change in the listing and future sole supply of Sodium Chloride Inj 0.9% 5 ml, 10 ml & 20 ml.
New listing from 1 July 2019
Sodium Chloride Inj 0.9% 5 ml 20 Fresenius Kabi Pharmacode 2565749 Schedule price $2.80
Sodium Chloride Inj 0.9% 10 ml 50 Fresenius Kabi Pharmacode 2565757 Schedule price $5.40
Sodium Chloride Inj 0.9% 20 ml 20 Fresenius Kabi Pharmacode 2565730 Schedule price $5.00
Sodium Chloride Inj 0.9% 5 ml 50 Multichem Pharmacode 2320541 Schedule price $7.00
Sodium Chloride Inj 0.9% 5 ml 50 InterPharma Pharmacode 2471094 Schedule price $7.00
Sodium Chloride Inj 0.9% 10 ml 50 Pfizer Pharmacode 691968 Schedule price $6.63
Sodium Chloride Inj 0.9% 20 ml 20 Multichem Pharmacode 2249200 Schedule price $5.00
Sodium Chloride Inj 0.9% 20 ml 30 InterPharma Pharmacode 2471116 Schedule price $7.50
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 December 2019.
Brand switch fee for Community Pharmacy has not been advised.
As of the date of this notification ProPharma / PWR cannot accept Sodium Chloride Inj 0.9% Pfizer, Multichem or InterPharma for credit under any circumstances.
We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.
You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 December 2019. Failure to do so may prove very costly.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 December 2019 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.